The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Book ForumFull Access

Correction

Published Online:https://doi.org/10.1176/ajp.158.10.1759

There was an error in one of the figures that appeared in the article, “A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective Disorder, “ by Robert R. Conley, M.D., and Ramy Mahmoud, M.D., M.P.H. (Am J Psychiatry 2001; 158:765–774). The corrected figure should replace Figure 3 on page 771.

Figure 3.

Figure 3. Percentages of Participants Treated With Risperidone or Olanzapine Who Were Rated Much or Very Much Improved on the Clinical Global Impression Change Scale at Weeks 2–8